Molecular mechanisms of cancer pain

Nature Reviews Cancer

Volumn 2, Issue 3, 2002, Pages 201-209

  Mantyh, Patrick W ^a   Clohisy, Denis R ^b   Koltzenburg, Martin ^c   Hunt, Steve P ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACID SENSING ION CHANNEL ANTAGONIST; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; GABAPENTIN; IBUPROFEN; LOCAL ANESTHETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OSTEOPROTEGERIN; PURINERGIC RECEPTOR BLOCKING AGENT; RECEPTOR BLOCKING AGENT; SAPORIN; SUBSTANCE P; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST;

ANTICHOLINERGIC EFFECT; ASEPTIC NECROSIS; BLEEDING; BONE MARROW SUPPRESSION; CANCER DIAGNOSIS; CANCER PAIN; CANCER PATIENT; CANCER THERAPY; CARDIOTOXICITY; CEILING EFFECT; CONSTIPATION; DIABETES MELLITUS; DISEASE CONTROL; DISEASE MODEL; DYSPEPSIA; DYSPHORIA; ELECTROLYTE DISTURBANCE; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTENSION; MOLECULAR MECHANICS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROBIOLOGY; OROPHARYNX; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; THRUSH; TISSUE INJURY; ULCER; VOMITING; WEIGHT GAIN; NEOPLASM; NOCICEPTIVE RECEPTOR; PAIN; PHYSIOLOGY; SENSORY NERVE; SENSORY NERVE CELL;

AFFERENT PATHWAYS; HUMANS; NEOPLASMS; NEURONS, AFFERENT; NOCICEPTORS; PAIN;

EID: 0036515869     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc747     Document Type: Review

References (122)

1. Mercadante, S. Malignant bone pain: pathophysiology and treatment. Pain 69, 1-18 (1997). Argues, based on the clinical literature, that bone metastases are the most common cause of cancer-related pain. It concludes that cancer pain compromises the patient's quality of life, and that the level of cancer pain is often disproportionate to the size of the tumour.
2. Mercadante, S. & Arcuri, E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat. Rev. 24, 425-432 (1998).
3. Portenoy, R. K. & Lesage, P. Management of cancer pain. Lancet 353, 1695-1700 (1999).
4. Portenoy, R. K., Payne, D. & Jacobsen, P. Breakthrough pan: characteristics and impact in patients with cancer pain. Pain 81, 129-134 (1999).
5. Hoskin, P. in Tumor Bone Diseases and Osteoporosis in Cancer Patients (ed. Body, J.-J.) 263-286 (Marcel Dekker, New York, 2000).
6. Coyle, N., Adelhardt, J., Foley, K. M. & Portenoy, R. K. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J. Pain Symptom Manage. 5, 83-93 (1990).
7. Payne, R. Mechanisms and management of bone pain. Cancer 80, 1608-1613 (1997).
8. Payne, R. et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J. Clin. Oncol. 16, 1588-1593 (1998).
9. Meuser, T. et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93, 247-257 (2001).
10. de Wit, R. et al. The Amsterdam Pain Management Index compared to eight frequently used outcome measures to evaluate the adequacy of pain treatment in cancer patients with chronic pain. Pain 91, 339-349 (2001).
11. Schwei, M. J. et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J. Neurosci. 19, 10886-10897 (1999). Describes the first animal model of cancer pain, showing a correlation between tissue-induced tumour destruction, neurochemical changes in sensory neurons and spinal cord, and the development of pain-related behaviours.
12. Honore, R. et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Med 6, 521-528 (2000). The first paper to use an animal model of cancer pain to test the usefulness of a novel analgesic therapy. The authors show that animal models of cancer pain can be used to examine the mechanism by which new therapies block cancer pain.
13. Luger, N. M. et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res. 61, 4038-4047 (2001). The first paper to examine the mechanisms that generate and maintain chronic pain in advanced stages of cancer. It was the first demonstration that novel therapies might be effective in controlling early- as well as late-stage cancer pain.
14. Djouhri, L., Bleazard, L. & Lawson, S. N. Association of somatic action potential shape with sensory receptive properties in guinea-pig dorsal root ganglion neurones. J. Physiol. 513, 857-872 (1998).
15. Basbaum, A. I. & Jessel, T. M. in Principles of Neural Science (eds Kandel, E. R., Schwartz, J. H. & Jessell, T. M.) 472-490 (McGraw-Hill, New York, 2000).
16. Julius, D. & Basbaum, A. I. Molecular mechanisms of nociception. Nature 413, 203-210 (2001). An elegant review of the signal-transduction mechanisms that are used by nociceptors to detect physiological stimuli. It also describes how nociceptor excitability is altered by a variety of intracellular signalling pathways.
17. Kirschstein, T. Greffrath, W., Busselberg, D. & Treede, R. D. Inhibition of rapid heat responses in nociceptive primary sensory of rats by vanilloid receptor antagonists. J. Neurophysiol 82, 2853-2860 (1999).
18. Welch, J. M., Simon, S. A. & Reinhart, P. H. The activation mechanism of rat vanilloid receptor 1 by capsaicin involves the core domain and differs from the activation by either or heat. Proc. Natl. Acad. Sci. USA 97, 13889-13894 (2000).
19. Bevan, S. & Geppetti, P. Protons: small stimulants of capsaicin-sensitive sensory nerves. Trends Neurosci. 17, 509-512 (1994).
20. Caterina, M. J. et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288, 306-313 (2000).
21. Nagy I. & Rang, H. Noxious heat activates all capsaicin-sensitive and also a sub-population of capsaicin-insensitive dorsal root ganglion neurons. Neuroscience 88, 995-997 (1999).
22. Tominaga, M. et al. The cloned capsaicin receptor integrate multiple pain-producing. Neuron 21, 531-543 (1998)
23. Price, M. P. et al. The DRASIC cation channel contributes to the detection of cutaneous touch and acid stimuli in mice. Neuron 32, 1071-1083 (2001). Shows that DRASIC subunits participate in a heteromultimeric channel and that, depending on the type of sensory neuron that is expressed, DRASIC might be a signal transducer for mechanical stimuli or for low pH.
24. Krishtal, O. A., Marchenko, S. M. & Obukhov, A. G. Cationic channels activated by extracellular ATP in rat sensory neurons. Neuroscience 27, 995-1000 (1988).
25. Xu, G. Y. & Huang, L. Y. M. Peripheral inflammation sensitizes P2X receptor-mediated responses in dorsal root ganglion neurons. J. Neurosci. 22, 93-102 (2002).
26. Nelson, J. B. & Carducci, M. A. The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU Intern. 85, 45-48 (2000).
27. Alvarez, F. J. & Fyffe, R. E. Nociceptors for the 21st century. Curr. Rev. Pain 4, 451-458 (2000).
28. McMahon, S. B. NGF as a mediator of inflammatory pain. Phil. Trans. R. Soc. Lond. B351, 431-440 (1996).
29. Woolf, C. J. & Salter M. W. Neuronal plasticity: increasing the gain in pain. Science 288, 1765-1769 (2000).
30. Schmidt, R. et al. Novel classes of responsive and unresponsive C nociceptors in human skin. J. Neurosci. 15, 333-341 (1995).
31. Honore, P. et al. Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog. Brain Res. 129, 389-397 (2000).
32. Honore, P., Menning, P. M., Rogers, S. D., Nichols, M. L. & Mantyh, P. W. Neurochemical plasticity in persistent inflammatory pain. Prog. Brain Res. 129, 357-363 (2000).
33. Mantyh, P. W. et al. Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. Proc. Natl Acad. Sci. USA 92, 2622-2626 (1995).
34. Mantyh, P. W. et al. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science 268, 1629-1632 (1995).
35. Hunt, S. P. & Mantyh, P. W. The molecular dynamics of pain control. Nature Rev. Neurosci. 2, 83-91 (2001). Evidence that pain has both discriminative and affective qualities, and that both are regulated in an activity-dependent fashion by ascending and descending modulatory systems.
36. Basbaum, A. I. Immediate-early genes and pain: what's all the 'Fos' about? APS J. 3, 49-52 (1994)
37. Jasmin, L., Wang, H., Tarczy-Hornoch, K., Levine, J. D. & Basbaum, A. I. Differential effects of morphine on noxious stimulus-evoked Fos-like immunoreactivity in subpopulations of spinoparabrachial neurons. J. Neurosci. 14, 7252-7260 (1994).
38. Doyle, C. A. & Hunt, S. P. Substance P receptor (neurokinin-1)-expressing neurons in lamina I of the spinal cord encode for the intensity of noxious stimulation: a c-Fos study in rat Neuroscience 89, 17-28 (1999).
39. Hunt, S. P., Pini, A. & Evan, G. Induction of c-Fos-like protein in spinal cord neurons following sensory stimulation. Nature 328, 632-634 (1987).
40. Abbadie, C., Taylor, B. K., Peterson, M. A. & Basbaum, A. I. Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Pain 69, 101-110 (1997).
41. Honore, P. et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98, 585-598 (2000). Establishes that a unique set of neurochemical changes occurs in the central peripheral and central nervous systems in cases of chronic inflammatory, neuropathic and cancer pain. These findings indicate that cancer induces a unique, persistent pain state.
42. Galasko, C. S. Diagnosis of skeletal metastases and assessment of response to treatment. Clin. Orthop. 312, 64-75 (1995).
43. Nielsen, O. S., Munro, A. J. & Tannock, I. F. Bone metastases: pathophysiology and management policy. J. Clin. Oncol. 9, 509-24 (1991).
44. DeLeo, J. A. & Yezierski, R. P. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90, 1-6 (2001).
45. Watkins, L. R., Maier, S. F. & Goenler, L. E. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states Pain 63, 289-302 (1995).
46. Watkins, L. R. & Maier, S. F. Implications of immune-to-brain communication for sickness and pain Proc. Natl Acad. Sci. USA 96, 7710-7713 (1999).
47. Nadler, R. B. et al. IL-1β and TNF-α in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J. Urol. 164, 214-218 (2000).
48. Davar, G. Endothelin-1 and metastatic cancer pain. Pain Med. 2, 24-27 (2001).
49. Opree, A. & Kress, M. Involvement of the proinflammatory cytokines tumor necrosis factor-α, IL-1β, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J. Neurosci. 20, 6289-6293 (2000).
50. Watkins, L. R., Goehler, L. E., Relton, J., Brewer, M. T. & Maier, S. F. Mechanisms of tumor necrosis factor-α (TNF-α) hyperalgesia. Brain Res. 692, 244-250 (1995).
51. Stoscheck, C. M. & King, L. E. Jr. Role of epidermal growth factor in carcinogenesis. Cancer Res. 48, 1030-1037 (1986).
52. Poon, R. T., Fan, S. T. & Wong, J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19, 1207-1225 (2001).
53. Roman, C., Saha, D. & Beauchamp, R. TGF-β and colorectal carcinogenesis. Microsc. Res. Tech. 52, 450-457 (2001).
54. Silver, B. J. Platelet-derived growth factor in human malignancy. Biofactors 3, 217-227 (1992).
55. Daughaday, W. H. & Deuel, T. F. Tumor secretion of growth factors. Endocrinol. Metab. Clin. N. Am. 20, 539-563 (1991).
56. Radinsky, R. Growth factors and their receptors in metastasis. Sem. Cancer Biol. 2, 169-177 (1991).
57. Vasko, M. R. Prostaglandin-induced neuropeptide release from spinal cord. Prog. Brain Res. 104, 367-380 (1995).
58. Shappell, S. B. et al. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 3, 287-303 (2001).
59. Kundu, N., Yang, Q. Y. Dorsey, R. & Fulton, A. M. Increased cyclooxygenase-2 (Cox-2) expression and activity in a murine model of metastatic breast cancer. Intern. J. Cancer 93, 681-686 (2001).
60. Ohno, R. et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma Cancer 91, 1876-1881 (2001).
61. Molina, M. A. Sitia-Arnau, M., Lemoine, M. G., Frazier, M. L. & Sinicrope, F. A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 59, 4356-4362 (1999).
62. Dubois, R. N., Radhika, A., Reddy, B. S. & Entingh, A. J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors Gastroenterology 110, 1259-1262 (1996).
63. Moore, B. C. & Simmons, D. L. COX-2 inhibition, apoptosis, and chemoprevention by nonsteroidal anti-inflammatory drugs. Curr. Med. Chem. 7, 1131-1144 (2000).
64. Masferrer, J. L. et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60, 1306-1311 (2000).
65. Fosslien, E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit. Rev. Clin. Lab. Sci. 37, 431-502 (2000).
66. Mercadante, S. The use of anti-inflammatory drugs in cancer pain. Cancer Treat. Rev. 27, 51-61 (2001).
67. Shankar, A. et al. Raised endothelin 1 levels in patients with colorectal liver metastases. Br. J. Surg. 85, 502-506 (1998).
68. Kurbel, S. et al. Endothelin-secreting tumors and the idea of the pseudoectopic hormone secretion in tumors. Med. Hypotheses 52, 329-333 (1999).
69. Nelson, J. B. et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med. 1, 944-949 (1995).
70. Pomonis, J. D., Rogers, S. D., Peters, C. M., Ghilardhi, J. R. & Mantyh, P. W. Expression and localization of endothelin receptors: implication for the involvement of peripheral glia in nociception. J. Neurosci. 21, 999-1006 (2001).
71. Davar, G., Hans, G., Fareed, M. U., Sinnott, C. & Strichartz, G. Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport 9, 2279-2283 (1998).
72. Dawas, K. Laizidou, M., Shankar, A. Ali, H. & Taylor, I. Angiogenesis in cancer: the role of endothelin-1. Ann. R. Coll. Surg. Engl. 81, 306-310 (1999).
73. Asham, E. H., Loizidou, M. & Taylor, I. Endothelin-1 and tumour development. Eur. J. Surg. Oncol. 24, 57-60 (1998).
74. Griffiths, J. R. Are cancer cells acidic? Br. J. Cancer 64, 425-427 (1991).
75. Reeh, P. W. & Steen, K. H. Tissue acidosis in nociception and pain. Prog. Brain Res. 113, 143-151 (1996).
76. Sutherland, S., Cook, S. & Ew, M. Chemical mediators of pain due to tissue damage and ischemia. Prog. Brain Res. 129, 21-38 (2000).
77. Olson, T. H. Riedl, M. S., Vulchanova, L., Ortiz-Gonzalez, X. R. & Elde, R. An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats. Neuroreport 9, 1109-1113 (1998).
78. Caterina, M. J. et al. The capsaicin receptor: a heat-activated ion channel in the pain. Nature 389, 816-824 (1997).
79. Tominaga, M. et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21, 531-543 (1998). A seminal paper showing that protons decrease the temperature threshold for VR1 activation, so that even moderately acidic conditions activate VR1 at room temperature. This paper established VR1 as a molecular integrator of noxious chemical and physical stimuli in nociceptors.
80. + channel with novel properties. J. Biol. Chem. 272, 28819-28822 (1997).
81. Lingueglia, E. et al. A modulatory subunit of acid sensing ion channels in brain and dorsal root ganglion cells. J. Biol. Chem. 212, 29778-29783 (1997).
82. Clohisy, D. R., Perkins, S. L. & Ramnaraine, M. L. Review of cellular mechanisms of tumor osteolysis. Clin Orthop. 373, 104-114 (2000).
83. Clohisy, D. R. et al. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone growth in osteopetrotic mice. J. Orthop. 18, 967-976 (2000).
84. Clohisy, D. R., O'Keefe, P. F. & Ramnaraine, M. L. Pamidronate decreases tumor-induced osteoclastogenesis in mice. J. Orthop. Res. 19, 554-558 (2001).
85. Delaisse, J.-M. & Vaes, G. in Biology and Physiology of the Osteoclast (eds Rifkin, B. R. & Gay, C. V.) 289-314 (CRC Press, Ann Arbor, 1992).
86. Guo, A., Vulchanova, L., Wang, J., D., X. & Elde, R. Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur. J. Neurosci. 11, 946-958 (1999).
87. Berenson, J. R. et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91, 1191-1200 (2001).
88. Fulfaro, F., Casuccio, A., Ticozzi, C. & Ripamonti, C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78, 157-169 (1998).
89. Major, P. P., Lipton, A., Berenson, J. & Hortobagyi, G. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 88, 6-14 (2000).
90. Rogers, M. J. et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88, 2961-2978 (2000).
91. Gatti, D. & Adami, S. New bisphosphonates in the treatment of bone diseases. Drugs Aging 15, 285-296 (1999).
92. Rodan, G. A. & Martin, T. J. Therapeutic approaches to bone diseases. Science 289, 1508-1514 (2000).
93. Hiraga, T. Williams, P. J., Mundy, G. R. & Yoneda, T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 61, 4418-4424 (2001).
94. Yoneda, T. et al. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88, 2970-2988 (2000).
95. Sasaki, A. et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55, 3551-3557 (1995).
96. Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
97. Anderson, D. M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179 (1997).
98. Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597-3602 (1998).
99. Hsu, H. L. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 96, 3540-3545 (1999).
100. Bekker, P. J. et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16, 348-360 (2001).
101. Terada, T. & Matsunaga, Y. S-100-positive nerve fibers in hepatocellular carcinoma and intrahepatic cholangiocarcinoma: an immunohistochemical study. Pathol. Int. 51, 89-93 (2001).
102. O'Connell, J. X. Nanthakumar, S. S., Nielsen, G. P. & Rosenberg, A. E. Osteoid osteoma: the uniquely innervated bone tumor. Modern Pathol. 11, 175-180 (1998).
103. Seifert, P. & Spitznas, M. Tumours may be innervated. Virchows Archiv. 438, 228-231 (2001).
104. Ripamonti, C. & Dickerson, E. D. Strategies for the treatment of cancer pain in the new millennium. Drugs 61, 955-977 (2001).
105. Lipton, R. B. et al. Taxol produces a predominantly sensory neuropathy. Neurology 39, 368-373 (1989).
106. Polomano, R. C., Mannes, A. J., Clark, U. S. & Bennett, G. J. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94, 293-304 (2001).
107. Polomano, R. C. & Bennett, G. J. Chemotherapy-evoked painful peripheral neuropathy. Pain Med. 2, 8-14 (2001).
108. Fukamachi, S. et al. Altered expressions of glutamate transporter subtypes in rat model of neonatal cerebral hypoxia-ischemia. Brain Res. Dev. Brain Res. 132, 131-139 (2001).
109. Rothstein, J. C., Martin, L. J. & Kuncl, R. W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 326, 1464-1468 (1992).
110. Laughlin, T. M. et al. Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain 72, 253-260 (1997).
111. Vanderah, T. W. et al. Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain 68, 275-281 (1996).
112. Vanderah, T. W., Ossipov, M. H., Lai, J., Malan, T. P. & Porreca, F. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain 92, 5-9 (2001).
113. Kajander, K. C., Sahara, Y., Iadarola, M. J. & Bennett, G. J. Dynorphin increases in the dorsal spinal cord in rats with a painful peripheral neuropathy. Peptides 11, 719-728 (1990).
114. Noguchi, K. et al. Dynorphin expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord neurons. Brain Res. Mol. Brain Res. 10, 227-233 (1991).
115. Dubner, R. & Ruda, M. A. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 15, 96-103 (1992)
116. Iadarola, M. J., Douglass, J., Civelli, O. & Naranjo, J. R. Differential activation of spinal cord dynorphin and enkephalin neurons during hyperalgesia: evidence using cDNA hybridization. Brain Res. 455, 205-212 (1988).
117. Imbe, H. & Ren, K. The up-regulation of preprodynorphin mRNA in trigeminoparabrachial neurons after inflammation. Neuroreport 11, 845-847 (2000).
118. MacArthur, L., Ran, K., Pfaffenroth, E., Franklin, E. & Ruda, M. A. Descending modulation of opioid-containing nociceptive neurons in rats with peripheral inflammation and hyperalgesia. Neuroscience 88, 499-506 (1999).
119. Nauta, H. J. W. et al. Punctate midline myelotomy for the relief of visceral cancer pain. J. Neurosurg. 92, 125-130 (2000). Clinical study showing that multiple pathways might be involved in the ascending conduction of visceral cancer pain - one reason that cancer pain can be difficult to fully control.
120. Willis, W. D., Al-Chaer, E. D., Quast, M. J. & Westlund, K. N. A visceral pain pathway in the dorsal column of the spinal cord. Proc. Natl Acad. Sci. USA 96, 7675-7679 (1999).
121. Lembeck, F. & Gamse, R. Substance P in peripheral sensory processes. Ciba Found. Symp. 91, 35-54 (1982).
122. Fields, H. Pain (McGraw-Hill, New York, 1987).